EBSEmergent BioSolutions Inc.

$446M

Q1 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$300M+82.8% YoY

Gross Profit

$141M46.9% margin

Operating Income

$40M13.2% margin

Net Income

$9M3.0% margin

EPS (Diluted)

$0.17

QoQ Revenue Growth

+8.6%

Cash Flow

Operating Cash Flow

-$63M

Free Cash Flow

-$73M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$1.8B

Total Liabilities

$1.1B

Stockholders' Equity

$664M

Cash & Equivalents

$79M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$300M	$164M	+82.8%
Gross Profit	$141M	-$24M	+679.4%
Operating Income	$40M	-$148M	+127.0%
Net Income	$9M	-$186M	+104.8%

Revenue Segments

Product

$274M91%

Contract Development And Manufacturing

$19M6%

Contracts and Grants

$8M3%

Geographic Segments

Services Segment

$19M100%

EBS Q1 2024 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena